1H-Pyrrole-3-Carboxamide, N-(2-(Diethylamino)Ethyl)-5-((Z)- (5-Fluoro-1,2-Dihydro-2-Oxo-3H-Indol-3-Ylidene)Methyl)-2,4- Dimethyl-

Commercial batches of immediate-release capsules delivering 12.5 mg, 25 mg, or 50 mg sunitinib base per unit are produced using the malate salt, where each 12.5 mg of the (Z)-isomer free base moiety is stoichiometrically equivalent to 16.7 mg of sunitinib malate. Intragranular excipients in the wet-granulated formulation typically comprise mannitol (Pearlitol 200SD) as a hydrophilic filler and diluent, crospovidone (Kollidon CL) as an intragranular disintegrant, and povidone (K30) dissolved in purified water as the binder solution. Granulation proceeds in a high-shear mixer (Diosna P 1/6) with impeller speed of 250±20 rpm and chopper at 1800 rpm until an end-point torque rise of 15–20% relative to dry mixing is reached; the wet mass is subsequently dried in a fluid-bed drier (Glatt GPCG 1) to a loss-on-drying value of 1.5–2.5% at 60±5°C inlet air temperature. After size reduction through a 1.0 mm oscillating screen, the granules are blended with extragranular crospovidone (half the total disintegrant) and magnesium stearate (0.5% w/w), lubricated for 5 minutes in a V-blender, and encapsulated on a Zanasi LZ-64 intermittent-motion machine into size 3 hard gelatin capsules. Capsule body and cap colors differentiate strengths: 12.5 mg — orange opaque / orange opaque; 25 mg — caramel opaque / white opaque; 50 mg — caramel opaque / caramel opaque, all imprinted with “Pfizer” on cap and “STN 12.5” (or corresponding) on body. The filled capsules comply with USP monograph dissolution requirements using Apparatus 2 (paddle) at 75 rpm in 900 mL of pH 6.8 phosphate buffer with 2.0% sodium lauryl sulfate, where a Q value of 80% dissolved in 45 minutes is required. Packaging in amber PVC/PCTFE blisters or HDPE bottles with desiccant is mandated because the Z-isomer photoisomerizes to the E-isomer under artificial laboratory light with an observed half-life below 24 hours; thus, all processing steps from granulation through packaging are conducted under low-level amber LED illumination (<200 lux).

What Carrier-to-Drug Ratio Determines Sustained Supersaturation in Biorelevant Fasted-State Simulated Intestinal Fluid?

Development of an amorphous solid dispersion (ASD) of the free base is necessitated by the pH-dependent aqueous solubility of the (Z)-isomer, which falls below 1 µg/mL at intestinal pH. Hot-melt extrusion (HME) on a co-rotating twin-screw extruder with a barrel length-to-diameter ratio of 40:1 (Leistritz ZSE 18 HP) melt-processes a physical mixture of sunitinib base and vinylpyrrolidone-vinyl acetate 64 copolymer (PVP-VA64) in a 1:4 (w/w) ratio at a barrel temperature profile from 140°C to 170°C, with a screw speed of 300 rpm and a feed rate adjusted to maintain a torque of 40–60%. The extrudate is chilled on a belt conveyor, cryogenically ground in a pin mill to a particle size D90 < 250 µm, and blended with extragranular crospovidone and colloidal silicon dioxide. Tablets compressed from the ASD granules achieve a supersaturation factor of 4–6 in FaSSIF media relative to the crystalline malate salt, with a precipitation induction time exceeding 90 minutes. Residual vinyl acetate monomer and pyrrolidone levels in the polymer comply with FDA Inactive Ingredient Guide limits and Ph. Eur. monographs; extrusion must be conducted under a nitrogen blanket to prevent thermo-oxidative degradation of the indolinone moiety. The finished tablets are packaged in alu-alu blisters with integrated desiccant, and real-time stability under 25°C/60%RH conditions per ICH Q1A confirms amorphous phase purity above 95% for 24 months.

Dry granulation of a sunitinib malate-based fixed-dose combination tablet with a co-administered crystalline anticancer agent is pursued when wet granulation induces polymorphic transition of the second drug substance. Roller compaction on a Gerteis Mini-Pactor equipped with smooth rolls at a specific compaction force of 8 kN/cm and gap width of 2.0 mm converts a pre-blend of the malate salt, microcrystalline cellulose (Avicel PH-101), crospovidone, and colloidal silicon dioxide into ribbons with a solid fraction between 0.55 and 0.70. Milling through a 1.0 mm oscillating screen produces granules with a bimodal size distribution; the fine fraction (< 75 µm) is recycled at 20% w/w of the total granulation to maintain compressibility. Addition of extragranular sodium stearyl fumarate (1.0% w/w) as a lubricant avoids magnesium stearate-induced dissolution retardation observed for the malate salt at long blend times. The final tablets, film-coated with Opadry II white, meet USP 〈905〉 uniformity of dosage units and deliver an f2 similarity factor above 50 in comparative dissolution against the reference monotherapy product in pH 6.8 SLS-containing medium. Regulatory filing follows the SUPAC-IR framework; post-approval stability under ICH conditions confirms no significant change in Z-isomer content or dissolution release rate over 36 months.

Photodegradation Kinetics in PVC/PVDC Blisters Versus HDPE Bottles Monitored at 25°C/60%RH Under ICH Q1B Confirmatory Conditions

Exposure of the (Z)-free base or its malate salt to artificial daylight (D65 lamp, 1.2 million lux·hours visible and 200 Wh/m² near UV) drives a photostationary state containing up to 15% of the less pharmacologically active E-isomer. Forced degradation studies in a Suntest CPS+ chamber reveal a half-life of the Z‑isomer below 8 hours in uncovered solution, while solid-state rate constants depend on packaging configuration. Tightly sealed HDPE bottles with a 35 mm child-resistant closure containing an integrated molecular sieve desiccant limit E-isomer accumulation to ≤0.5% after 18 months under accelerated conditions, whereas PVC/PVDC blister packs without opaque overwrap permit migration to 1.8% within 12 months. Therefore, secondary packaging must include an overwrapped aluminium pouch if a blister primary package is selected. All incoming raw material lots of the (Z)-isomer are tested by a stability-indicating HPLC method (C18 column, 250 × 4.6 mm, 5 µm, mobile phase acetonitrile : ammonium acetate buffer pH 5.0 60:40 v/v, detection at 367 nm) with a limit of quantitation for the E-isomer of 0.05%. Processing facilities handling the compound install amber LED panels (peak wavelength 590 nm) maintaining illuminance below 200 lux at operator level; routine environmental monitoring records time-stamped lux readings during weighing, granulation, and encapsulation.

A working standard batch of the (Z)-isomer free base intended as a secondary or in-house reference material is recrystallized from a ternary solvent system composed of tetrahydrofuran, acetone, and water (volume ratio 5:3:2) under amber lighting and dried in a vacuum oven at 40°C and ≤5 mbar for 48 hours. The dried substance is micronized in a fluid‑jet mill with nitrogen gas protection to a particle size D50 of 5–15 µm and dispensed into amber glass vials under a dry nitrogen headspace. Assignment of the 99.5% (anhydrous, solvent‑free) minimum purity relies on mass balance derived from HPLC area normalization, residual loss on drying (<0.5%), sulfated ash (<0.1%), and headspace GC quantitation of methylene chloride (<60 ppm) and N,N‑dimethylformamide (<880 ppm) in accordance with ICH Q3C Class 2 limits. Traceability is established through co‑analysis with USP Sunitinib Malate RS (current lot) using the monograph system suitability criteria: resolution between Z‑isomer and E‑isomer peaks not less than 2.5, tailing factor ≤2.0, and relative standard deviation for replicate injections ≤1.0%. This characterized working standard is subsequently used to calibrate HPLC detectors for batch release testing of commercial capsules, for polymorphism screening by XRPD, and for content uniformity assays during process validation runs of at least 30,000 dosage units. Storage at −20°C in a desiccated environment retards Z‑to‑E conversion and oxidative degradation of the pyrrole carboxamide moiety, extending the re‑qualification interval to 24 months compared with 12 months at 4°C.

If Preclinical Pharmacokinetics Require Constant‑Rate Intravenous Infusion of a Weakly Basic Molecule, the Infusate Must Be Buffered to pH 3.5–4.5 to Maintain Complete Solubilization of the Malate Salt

Preparation of a micro‑dosing solution for rodent or canine infusion studies begins by dissolving a pre‑weighed quantity of sunitinib malate in degassed dimethyl sulfoxide to a concentration not exceeding 50 mg/mL to limit haemolytic potential upon dilution. This stock is immediately diluted at least 20‑fold into sterile 0.9% sodium chloride for injection or 5% dextrose containing 20% (w/v) sulfobutylether‑β‑cyclodextrin (Captisol®) as a solubilising and stabilising excipient. The pH is adjusted to 4.0 ± 0.5 with 0.1 N hydrochloric acid, and the vessel is wrapped in amber foil to maintain illuminance below 50 lux during handling. Terminal sterilisation is accomplished by passage through a 0.22 µm PVDF filter under positive nitrogen pressure; the sterile filtrate is aliquoted into amber Type I glass vials, stoppered, and used within 8 hours of preparation to avoid precipitation of the free base which starts at pH values exceeding 5.5. A pre‑clinical bridging strategy qualifying this procedure under GLP principles requires simultaneous analysis of Z‑isomer purity, osmolality (270–328 mOsm/kg), and sub‑visible particle counts per USP 〈788〉. Dosing accuracy at nominal infusion rates of 0.5–2 mL/kg/h is verified gravimetrically on the day of administration. When the protocol demands co‑administration of a positron emission tomography tracer, the stability of sunitinib in the mixed infusion in the presence of 10% ethanol (v/v) as a cosolvent must be confirmed over the infusion duration by HPLC‑UV at 367 nm.